Global News and Digital Insights
for the Healthcare Industry

Suven Pharmaceuticals surges over 13% on merger proposal with Cohance Lifesciences

Suven Pharmaceuticals Ltd. witnessed a significant surge of over 13% in its shares, reaching their highest point in over a month, following the announcement of a proposed merger with Cohance Lifesciences Ltd. As per the scheme outlined in an exchange filing, upon the merger’s implementation, shareholders of Cohance will receive 11 shares of Suven for every 295 shares they hold in Cohance. The news propelled Suven Pharma’s shares on the NSE, where they rose by as much as 13.10%. This strategic move marks a significant development for both companies, potentially reshaping their future trajectories in the pharmaceutical industry.

Read more from Ndtvprofit
Facebook
Twitter
LinkedIn